Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andro Classified As Controlled Substance In Senate Bill; DHEA Excluded

This article was originally published in The Tan Sheet

Executive Summary

Androstenedione would be regulated as a controlled substance under legislation offered by Sen. Joseph Biden (D-Del.), and co-sponsored by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) and Charles Grassley (R-Iowa)

You may also be interested in...



Steroid class action certified on appeal

A California appellate court in Los Angeles sides with a class action certification attempt on appeal against GNC about steroid-containing supplements. The court's Jan. 21 1decision reverses a lower court's rejection of plaintiff Diego Martinez's class certification attempt. The previous rejection was based on an erroneous legal assumption - "that common issues did not predominate because class members would be required to individually litigate issues of causation and injury." Martinez attempted to certify a class of anyone who purchased products from GNC containing androstenediol in California between 2000 and 2004. He alleged damages based on GNC's deceptive conduct. GNC said it ceased selling so-called supplements with androstenediol, a schedule III controlled substance, in March 2004 (2"The Tan Sheet" Oct. 27, 2003)

Steroid class action certified on appeal

A California appellate court in Los Angeles sides with a class action certification attempt on appeal against GNC about steroid-containing supplements. The court's Jan. 21 1decision reverses a lower court's rejection of plaintiff Diego Martinez's class certification attempt. The previous rejection was based on an erroneous legal assumption - "that common issues did not predominate because class members would be required to individually litigate issues of causation and injury." Martinez attempted to certify a class of anyone who purchased products from GNC containing androstenediol in California between 2000 and 2004. He alleged damages based on GNC's deceptive conduct. GNC said it ceased selling so-called supplements with androstenediol, a schedule III controlled substance, in March 2004 (2"The Tan Sheet" Oct. 27, 2003)

Steroid class action certified on appeal

A California appellate court in Los Angeles sides with a class action certification attempt on appeal against GNC about steroid-containing supplements. The court's Jan. 21 1decision reverses a lower court's rejection of plaintiff Diego Martinez's class certification attempt. The previous rejection was based on an erroneous legal assumption - "that common issues did not predominate because class members would be required to individually litigate issues of causation and injury." Martinez attempted to certify a class of anyone who purchased products from GNC containing androstenediol in California between 2000 and 2004. He alleged damages based on GNC's deceptive conduct. GNC said it ceased selling so-called supplements with androstenediol, a schedule III controlled substance, in March 2004 (2"The Tan Sheet" Oct. 27, 2003)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel